SG/CALL/EVOTEC/14/1/20.09.24 Share Price

Warrant

DE000SU65LY5

Market Closed - Boerse Frankfurt Warrants 20:42:03 28/06/2024 BST
0.19 EUR +26.67% Intraday chart for SG/CALL/EVOTEC/14/1/20.09.24
Current month+46.15%
1 month-5.00%
Date Price Change
28/06/24 0.19 +26.67%
27/06/24 0.15 -25.00%
26/06/24 0.2 +25.00%
25/06/24 0.16 +33.33%
24/06/24 0.12 +9.09%

Real-time Boerse Frankfurt Warrants

Last update June 28, 2024 at 08:42 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying EVOTEC SE
IssuerLogo Issuer Société Générale Société Générale
WKN SU65LY
ISINDE000SU65LY5
Date issued 19/01/2024
Strike 14
Maturity 20/09/2024 (82 Days)
Parity 1 : 1
Emission price 2.85
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 3.63
Lowest since issue 0.011
Delta0.16x
Omega 6.050
Premium58.61x
Gearing38.19x
Moneyness 0.6411
Difference Strike 5.025
Difference Strike %+35.89%
Spread 0.09
Spread %32.14%
Theoretical value 0.2450
Implied Volatility 77.70 %
Total Loss Probability 91.26 %
Intrinsic value 0.000000
Present value 0.2450
Break even 14.25 €
Theta-0.03x
Vega0.01x
Rho0x

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.975 EUR
Average target price
20.79 EUR
Spread / Average Target
+131.64%
Consensus